ACHIEVE
Completed study Official Study Title Anti-inflammatory ClaritHromycin to ImprovE SARS-CoV-2 (COVID-19) infection Early: The ACHIEVE open-label non-randomized clinical trial Brief Description ACHIEVE is an open non-randomized clinical trial aiming to prove that the addition of oral clarithromycin to treatment regimen of COVID-19 is associated with early clinical improvement and attenuation of the high inflammatory
SAVE
Completed study Official Study Title suPAR-guided Anakinra treatment for Validation of the risk and Early management of severe respiratory failure by COVID-19: the SAVE open-label, non-randomized single-arm trial Brief Description SAVE is an open non-randomized clinical trial aiming to study the early treatment of patients with COVID-19 pneumonia with anakinra guided by the biomarker
ESCAPE
Completed study Official Study Title Efficiency in management of organ dysfunction associated with infection by the novel SARS-Cov-2 virus through A PErsonalized immunotherapy approach Brief Description ESCAPE is an open non-randomized clinical trial aiming to the personalized therapy of patients with COVID-19. Using biomarkers, enrolled patients are receiving treatment with intravenous anakinra or intravenous
INCREDIBLE-ME
Ongoing study Official Study Title Gut-derived INCREtin hormones in the pathophysiology of Type 1 DiaBetes MeLlitus; Effect of Metformin treatment (the INCREDIBLE-ME trial) Brief Description INCREDIBLE-ME is a randomized clinical trial aiming to study the effect of adjunct metformin treatment to insulin monotherapy in patients with type 1 diabetes, targeting the intestinal incretin secretion.
PROUD-1
Completed study Official Study Title Pulse PhotoplethysmogAaphy as an early tool for the diagnosis of sepsis thrOUgh a two-stage Development approach Brief Description PROUD-1 is an interventional trial aiming to validate the diagnostic accuracy of a new optical biosensor for the diagnosis of sepsis and for COVID-19. Details Status: Completed Study Type: Interventional
HALO
Completed study Official Study Title Heparin AnticoaguLation to improve Outcomes in septic shock: The HALO international phase II RCT Brief Description HALO-HCA2017 is a randomized clinical trial aiming to study if heparin, a widely available, inexpensive anticoagulant, may improve clinical outcomes in patients with septic shock. Details Status: Completed Study Type: Interventional (Clinical